Lipid Nanocarrier-Based mRNA Therapy: Challenges and Promise for Clinical Transformation

被引:6
|
作者
Li, Wenchao [1 ,2 ,3 ,4 ]
Wang, Chen [1 ,2 ]
Zhang, Yifei [3 ,4 ]
Lu, Yuan [1 ,2 ]
机构
[1] Tsinghua Univ, Dept Chem Engn, Beijing 100084, Peoples R China
[2] Tsinghua Univ, Key Lab Ind Biocatalysis, Minist Educ, Beijing 100084, Peoples R China
[3] Beijing Univ Chem Technol, State Key Lab Chem Resource Engn, Beijing 100029, Peoples R China
[4] Beijing Univ Chem Technol, Beijing Adv Innovat Ctr Soft Matter Sci & Engn, Beijing 100029, Peoples R China
基金
国家重点研发计划; 中国国家自然科学基金;
关键词
clinical transformation; lipid composition; lipid nanocarrier; mRNA delivery; CANCER-THERAPY; RABIES VACCINE; IN-VIVO; DELIVERY; LIPOSOMES; NANOPARTICLES; EXOSOMES; NANOFORMULATIONS; TRANSLATION; STRATEGIES;
D O I
10.1002/smll.202310531
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Due to the outbreak of novel coronavirus pneumonia, messenger RNA (mRNA) technology has attracted heated attention. A specific, safe, and efficient mRNA delivery system is needed. Lipid nanocarriers have become attractive carriers for mRNA delivery due to their high delivery efficiency, few side effects, and easy modification to change their structures and functions. To achieve the desired biological effect, lipid nanocarriers must reach the designated location for effective drug delivery. Therefore, the effects of the composition of lipid nanocarriers on their key properties are briefly reviewed. In addition, the progress of smart drug delivery by changing the composition of lipid nanocarriers is summarized, and the importance of component design and structure is emphasized. Subsequently, this review summarizes the latest progress in lipid nanocarrier-based mRNA technology and provides corresponding strategies for its current challenges, putting forward valuable information for the future design of lipid nanocarriers and mRNA. Benefiting from the development of lipid nanocarriers and mRNA technologies, lipid nanocarrier-based mRNA therapies are being developed for use in infectious disease vaccines, cancer immunotherapy, gene editing, and protein replacement therapy. Various methods for optimizing lipid nanocarriers are developed to overcome the targeting, stability, safety, and repeatability of delivery systems. image
引用
收藏
页数:21
相关论文
共 50 条
  • [41] Network-based drugs: promise and clinical challenges in cardiovascular disease
    Roukos, Dimitrios H.
    Katsouras, Christos S.
    Baltogiannis, Giannis G.
    Naka, Katerina K.
    Michalis, Lampros K.
    EXPERT REVIEW OF PROTEOMICS, 2013, 10 (02) : 119 - 122
  • [42] Lipid-based nanocarrier mediated CRISPR/Cas9 delivery for cancer therapy
    Aziz, Aisha
    Rehman, Urushi
    Sheikh, Afsana
    Abourehab, Mohammed A. S.
    Kesharwani, Prashant
    JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION, 2023, 34 (03) : 398 - 418
  • [43] Pluripotent Stem Cell-Based Cell Therapy- Promise and Challenges
    Yamanaka, Shinya
    CELL STEM CELL, 2020, 27 (04) : 523 - 531
  • [44] Multifunctional HER2-Antibody Conjugated Polymeric Nanocarrier-Based Drug Delivery System for Multi-Drug-Resistant Breast Cancer Therapy
    Vivek, Raju
    Thangam, Ramar
    NipunBabu, Varukattu
    Rejeeth, Chandrababu
    Sivasubramanian, Srinivasan
    Gunasekaran, Palani
    Muthuchelian, Krishnasamy
    Kannan, Soundarapandian
    ACS APPLIED MATERIALS & INTERFACES, 2014, 6 (09) : 6469 - 6480
  • [45] A lipid nanoparticle-based oligodendrocyte-specific mRNA therapy
    Sawamura, Masanori
    Tachikawa, Kiyoshi
    Hikawa, Rie
    Akiyama, Hisako
    Kaji, Seiji
    Yasuda, Ken
    Leu, Angel I.
    Hong, Hyojung
    Mukthavaram, Rajesh
    Chivukula, Pad
    Yamakado, Hodaka
    Hirabayashi, Yoshio
    Takahashi, Ryosuke
    Matsuzawa, Shu-ichi
    MOLECULAR THERAPY NUCLEIC ACIDS, 2024, 35 (04):
  • [46] Rational Design of Metal Organic Framework Nanocarrier-Based Codelivery System of Doxorubicin Hydrochloride/Verapamil Hydrochloride for Overcoming Multidrug Resistance with Efficient Targeted Cancer Therapy
    Zhang, Huiyuan
    Jiang, Wei
    Liu, Ruiling
    Zhang, Jing
    Zhang, Di
    Li, Zhonghao
    Luan, Yuxia
    ACS APPLIED MATERIALS & INTERFACES, 2017, 9 (23) : 19687 - 19697
  • [47] Gene-based therapy in lipid management: the winding road from promise to practice
    Tromp, Tycho R.
    Stroes, Erik S. G.
    Hovingh, G. Kees
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (05) : 483 - 493
  • [48] Design of lipid-based nanocarrier for drug delivery has a double therapy for six common pathogens eradication
    Sharaf, Mohamed
    Hamouda, H., I
    Shabana, Samah
    Khan, Sohaib
    Arif, Muhammad
    Rozan, Hussein E.
    Abdalla, Mohnad
    Chi, Zhe
    Liu, Chenguang
    COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS, 2021, 625
  • [49] Transforming the Promise of Pluripotent Stem Cell-Derived Cardiomyocytes to a Therapy: Challenges and Solutions for Clinical Trials
    Prowse, Andrew B. J.
    Timmins, Nicholas E.
    Yau, Terrence M.
    Li, Ren-Ke
    Weisel, Richard D.
    Keller, Gordon
    Zandstra, Peter W.
    CANADIAN JOURNAL OF CARDIOLOGY, 2014, 30 (11) : 1335 - 1349
  • [50] Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges
    Tongers, Joern
    Losordo, Douglas W.
    Landmesser, Ulf
    EUROPEAN HEART JOURNAL, 2011, 32 (10) : 1197 - U166